ACC.26 News
Latest articles and news about ACC.26 on AXL Media.
Latest Articles
- Major Clinical Trial Finds Stopping Beta-Blockers is Safe for Low-Risk Patients One Year After Heart Attack
Published: Mar 31, 2026
Section: Science & Tech
A large-scale study presented at the American College of Cardiology’s Annual Scientific Session (ACC.26) suggests that stable patients without heart failure can safely discontinue...
- FDA Designated Breakthrough AI Analyzes Eye Scans to Predict Heart Disease Risk During Routine Optometry Appointments
Published: Mar 31, 2026
Section: Health
A clinical trial presented at the American College of Cardiology’s Annual Scientific Session (ACC.26) has demonstrated that the AI system CLAiR can accurately identify cardiovascul...
- Clinical Trial Data Reveals Potent Triglyceride Lowering Drug Olezarsen Fails to Reduce Coronary Plaque Volume After One Year of Treatment
Published: Mar 31, 2026
Section: Health
A sub-study presented at the American College of Cardiology’s Annual Scientific Session (ACC.26) found that while the drug olezarsen slashed triglyceride levels by 60%, it did not...
- Transcatheter Valve-in-Valve Procedure Slashes Death and Stroke Rates Compared to Redo Open-Heart Surgery
Published: Mar 30, 2026
Section: Medical News
Data from the SURVIV trial presented at the American College of Cardiology’s Annual Scientific Session reveals that a minimally invasive valve-in-valve procedure significantly outp...
- Deferring Coronary Intervention Before Aortic Valve Replacement Proves Safe for High Risk Elderly Patients
Published: Mar 30, 2026
Section: Science & Tech
Results from the PRO-TAVI trial indicate that older patients requiring both heart valve replacement and arterial stenting experience comparable outcomes whether they receive the pr...
- Mass General Brigham Study Finds Intensive Cholesterol Treatment Cuts First-Time Heart Events by Thirty-One Percent in Diabetic Patients
Published: Mar 30, 2026
Section: Research
A new analysis from the VESALIUS-CV trial presented at ACC.26 reveals that the PCSK9 inhibitor evolocumab significantly benefits high-risk diabetic patients before they develop kno...
- Phase 2 Trial of Investigational Hypertension Injection Tonlamarsen Reveals Persistent Protein Suppression but Conflicting Blood Pressure Data
Published: Mar 30, 2026
Section: Science & Tech
Results from the Kardinal trial presented at ACC.26 show that the monthly injectable drug tonlamarsen successfully reduces angiotensinogen levels by over 67%. However, the study fo...
- Home Delivery of DASH Diet Groceries Achieves Medication-Level Reductions in Blood Pressure for High-Risk Black Adults
Published: Mar 30, 2026
Section: Health
The GoFreshRx trial presented at ACC.26 demonstrates that providing dietitian-guided home grocery deliveries significantly improves cardiovascular health for Black adults in food d...
- New Trial Results Prove PCSK9 Inhibitors Reduce Major Cardiovascular Events by Thirty-One Percent in High-Risk Diabetic Patients
Published: Mar 30, 2026
Section: Research
A landmark subgroup analysis of the VESALIUS-CV trial presented at ACC.26 reveals that the cholesterol-lowering drug evolocumab provides significant protective benefits for diabeti...
- New Clinical Trial Reveals Cholesterol-Lowering Injection Reduces Major Heart Events by Thirty-One Percent in High-Risk Diabetic Patients
Published: Mar 30, 2026
Section: Medical News
A landmark subgroup analysis of the VESALIUS-CV trial presented at ACC.26 shows that the PCSK9 inhibitor evolocumab significantly benefits diabetic patients even before the develop...
- New Trial Shows Aggressive Cholesterol Targets Reduce Major Cardiovascular Events by One Third in High Risk Patients
Published: Mar 30, 2026
Section: Health
The Ez-PAVE trial presented at ACC.26 confirms that lowering LDL cholesterol to a target of less than 55 mg/dL significantly improves outcomes for patients with atherosclerotic dis...
- Landmark Placebo Controlled Trial Proves Angioplasty Significantly Relieves Chest Pain for Patients With Total Heart Blockages
Published: Mar 30, 2026
Section: Health
The ORBITA-CTO trial presented at ACC.26 provides the first double-blind evidence that reopening chronically blocked coronary arteries through angioplasty is an effective treatment...